AG
TXMD icon

Aperio Group’s TherapeuticsMD TXMD Stock Holding History

Aperio Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$65K Buy
1,077
+19
+2% +$1.3K ﹤0.01% 2400
2020
Q3 		$84K Sell
1,058
-594
-36% -$47.3K ﹤0.01% 2329
2020
Q2 		$103K Buy
1,652
+760
+85% +$44.2K ﹤0.01% 2272
2020
Q1 		$47K Sell
892
-3
-0.3% -$297 ﹤0.01% 2280
2019
Q4 		$109K Sell
895
-81
-8% -$11.6K ﹤0.01% 2255
2019
Q3 		$178K Buy
976
+384
+65% +$54.1K ﹤0.01% 2185
2019
Q2 		$77K Buy
592
+276
+87% +$49.5K ﹤0.01% 2457
2019
Q1 		$78K Buy
316
+50
+19% +$13.2K ﹤0.01% 2253
2018
Q4 		$51K Sell
266
-52
-16% -$12.7K ﹤0.01% 2259
2018
Q3 		$104K Sell
318
-37
-10% -$11.3K ﹤0.01% 2250
2018
Q2 		$111K Sell
355
-455
-56% -$139K ﹤0.01% 2218
2018
Q1 		$197K Buy
810
+138
+21% +$38.7K ﹤0.01% 2146
2017
Q4 		$203K Sell
672
-13
-2% -$3.62K ﹤0.01% 2137
2017
Q3 		$181K Buy
685
+14
+2% +$4.05K ﹤0.01% 2133
2017
Q2 		$177K Sell
671
-15
-2% -$3.76K ﹤0.01% 2126
2017
Q1 		$247K Buy
686
+185
+37% +$57.3K ﹤0.01% 1924
2016
Q4 		$145K Buy
501
+20
+4% +$6.2K ﹤0.01% 2050
2016
Q3 		$163K Buy
+481
New +$176K ﹤0.01% 1980
2014
Q4 		– Sell
-270
Closed -$63K – 1907
2014
Q3 		$63K Buy
+270
New +$68K ﹤0.01% 1712

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Aperio Group's TXMD Position: Q4 2020 in Review

Aperio Group increased its TherapeuticsMD (TXMD) stake by 1.8% in Q4 2020, buying an estimated $1.3K and bringing the position to 1,077 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #2400.

Aperio Group first reported a position in TXMD in Q3 2014 and has held it in 19 quarters since. The position peaked at $247K in Q1 2017. 159 funds tracked by Wall St. Rank hold TXMD as of Q4 2020.

  • Aperio Group held 1,077 shares of TherapeuticsMD worth $65K as of Q4 2020.
  • Aperio Group bought 19 TherapeuticsMD shares in Q4 2020, an estimated $1.3K.
  • TherapeuticsMD made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2400 holding.
  • Aperio Group first reported a position in TherapeuticsMD in Q3 2014 and has held it in 19 quarters since.
  • Aperio Group's TherapeuticsMD position peaked at $247K in Q1 2017.
  • 159 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.